Q-omics provides the consensus-scored DNAJC22 profile across patient tissues and cancer cell-line models. DNAJC22 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DNAJC22 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, DNAJC22 RNA expression shows 19,404 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where DNAJC22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC22 survival associations across molecular data types. DNAJC22 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC22 RNA expression–survival associations across cancer types. High DNAJC22 expression shows unfavorable associations in ACC, LGG, LUAD and BLCA, but favorable associations in KIRC and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DNAJC22 RNA expression.
This table summarizes DNAJC22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DNAJC22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC22 shows lower tumor expression in KICH and higher tumor expression in KIRC, LUAD, BLCA, STAD and HNSC. The KIRC box plot shows higher DNAJC22 RNA expression in tumor versus normal tissue (log2 FC = +1.571, t-test p < 0.001).
This table shows molecular features associated with DNAJC22 in patient tissues and cancer cell lines. In patient samples, DNAJC22 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BREAST.
